Next Article in Journal
Water-Soluble Melanoidin Pigment as a New Antioxidant Component of Fermented Willowherb Leaves (Epilobium angustifolium)
Previous Article in Journal
A Novel Immunoassay for Malondialdehyde-Conjugated Low-Density Lipoprotein Measures Dynamic Changes in the Blood of Patients Undergoing Coronary Artery Bypass Graft Surgery

Tumor-Induced Cardiac Dysfunction: A Potential Role of ROS

Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210, USA
Institute for Behavioral Medicine Research, Departments of Psychiatry and Behavioral Health & Neuroscience, The Ohio State University, Columbus, OH 43210, USA
Department of Pharmaceutical and Biomedical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810, USA
Division of Cardiovascular Medicine, Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
Authors to whom correspondence should be addressed.
Academic Editors: Nicola King and M.-Saadeh Suleiman
Antioxidants 2021, 10(8), 1299;
Received: 8 July 2021 / Revised: 9 August 2021 / Accepted: 12 August 2021 / Published: 18 August 2021
(This article belongs to the Special Issue Oxidative Stress in Cardiac Disease)
Cancer and heart diseases are the two leading causes of mortality and morbidity worldwide. Many cancer patients undergo heart-related complications resulting in high incidences of mortality. It is generally hypothesized that cardiac dysfunction in cancer patients occurs due to cardiotoxicity induced by therapeutic agents, used to treat cancers and/or cancer-induced cachexia. However, it is not known if localized tumors or unregulated cell growth systemically affect heart function before treatment, and/or prior to the onset of cachexia, hence, making the heart vulnerable to structural or functional abnormalities in later stages of the disease. We incorporated complementary mouse and Drosophila models to establish if tumor induction indeed causes cardiac defects even before intervention with chemotherapy or onset of cachexia. We focused on one of the key pathways involved in irregular cell growth, the Hippo–Yorkie (Yki), pathway. We used overexpression of the transcriptional co-activator of the Yki signaling pathway to induce cellular overgrowth, and show that Yki overexpression in the eye tissue of Drosophila results in compromised cardiac function. We rescue these cardiac phenotypes using antioxidant treatment, with which we conclude that the Yki induced tumorigenesis causes a systemic increase in ROS affecting cardiac function. Our results show that systemic cardiac dysfunction occurs due to abnormal cellular overgrowth or cancer elsewhere in the body; identification of specific cardiac defects associated with oncogenic pathways can facilitate the possible early diagnosis of cardiac dysfunction. View Full-Text
Keywords: heart failure; cancer; mitochondria; reactive oxygen species; Hippo–Yorkie pathway heart failure; cancer; mitochondria; reactive oxygen species; Hippo–Yorkie pathway
Show Figures

Graphical abstract

MDPI and ACS Style

Karekar, P.; Jensen, H.N.; Russart, K.L.G.; Ponnalagu, D.; Seeley, S.; Sanghvi, S.; Smith, S.A.; Pyter, L.M.; Singh, H.; Gururaja Rao, S. Tumor-Induced Cardiac Dysfunction: A Potential Role of ROS. Antioxidants 2021, 10, 1299.

AMA Style

Karekar P, Jensen HN, Russart KLG, Ponnalagu D, Seeley S, Sanghvi S, Smith SA, Pyter LM, Singh H, Gururaja Rao S. Tumor-Induced Cardiac Dysfunction: A Potential Role of ROS. Antioxidants. 2021; 10(8):1299.

Chicago/Turabian Style

Karekar, Priyanka, Haley N. Jensen, Kathryn L.G. Russart, Devasena Ponnalagu, Sarah Seeley, Shridhar Sanghvi, Sakima A. Smith, Leah M. Pyter, Harpreet Singh, and Shubha Gururaja Rao. 2021. "Tumor-Induced Cardiac Dysfunction: A Potential Role of ROS" Antioxidants 10, no. 8: 1299.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop